OSE 免疫治疗疗法,Inserm Transportt和Nantes大学合作伙伴,以推进癌症和天免疫机能疾病的免疫治疗。 OSE Immunotherapeutics, Inserm Transfert, and Nantes University partner to advance immunotherapies for cancer and autoimmune diseases.

OSE 免疫治疗、Inserm Transportt和Nantes大学建立了伙伴关系,推动癌症、炎症和自发免疫疾病的免疫治疗研究。 OSE Immunotherapeutics, Inserm Transfert, and Nantes University have formed a partnership to advance immunotherapy research for cancer, inflammation, and autoimmune diseases. 合作将南特大学和因塞姆大学的学术发现与OSE的发展专长联系起来,目的是将有前途的研究转化为可行的疗法。 The collaboration connects academic discoveries from Nantes University and Inserm with OSE’s development expertise, aiming to turn promising research into viable therapies. Insem Transportt将确定高潜力项目,提供资金和指导,以加快项目进展。 Inserm Transfert will identify high-potential projects, providing funding and guidance to accelerate their progress. 该联盟加强了南特的免疫治疗创新中心,并可以在全国推广这一公私模式。 The alliance strengthens the Immunotherapy Innovation Hub in Nantes and could expand this public-private model nationally. 它支持开放研究、技术转让和解决未满足的医疗需要,反映了法国为将学术创新与生物技术工业能力联系起来而作出的更广泛努力。 It supports open research, technology transfer, and addressing unmet medical needs, reflecting a broader effort to bridge academic innovation with biotech industry capabilities in France.